Evercore ISI Names Top 3 Tech Stocks for 2025
Evercore ISI analyst Amit Daryanani recommends Apple, Amphenol, and Arista Networks as top tech stocks for 2025, projecting growth driven by AI and broader IT spending recovery; Apple's market cap nears $4 trillion, Amphenol shows potential for double-digit revenue growth, and Arista Networks is poi...
Evercore ISI Names Top 3 Tech Stocks for 2025
Evercore ISI analyst Amit Daryanani recommends Apple, Amphenol, and Arista Networks as top tech stocks for 2025, projecting growth driven by AI and broader IT spending recovery; Apple's market cap nears $4 trillion, Amphenol shows potential for double-digit revenue growth, and Arista Networks is poi...
Progress
48% Bias Score
Trump Policies Spark Investor Fears, Underscoring Need for Cautious Investment Strategies
Concerns rise among investors about President-elect Trump's potential negative impact on the stock market; a Vanguard study reveals that 86% of investors who sold stocks during the 2020 pandemic underperformed those who stayed invested; the article advises against panic selling and suggests building...
Trump Policies Spark Investor Fears, Underscoring Need for Cautious Investment Strategies
Concerns rise among investors about President-elect Trump's potential negative impact on the stock market; a Vanguard study reveals that 86% of investors who sold stocks during the 2020 pandemic underperformed those who stayed invested; the article advises against panic selling and suggests building...
Progress
48% Bias Score
Five TFSA Investment Strategies for 2025
Five TFSA investment strategies for 2025 are presented, ranging from all-equity ETFs (high risk/return) to low-volatility ETFs, one-year GICs (low risk/return), utility stocks (moderate risk/return), and US dollar investments (currency risk).
Five TFSA Investment Strategies for 2025
Five TFSA investment strategies for 2025 are presented, ranging from all-equity ETFs (high risk/return) to low-volatility ETFs, one-year GICs (low risk/return), utility stocks (moderate risk/return), and US dollar investments (currency risk).
Progress
36% Bias Score
Meta Stock Soars 70% in 2024 Despite Regulatory and Political Uncertainties
Meta Platforms' stock price increased 70% year-to-date in 2024 due to increased operating margin (156%) and AI investments, despite concerns about 2024 revenue guidance and capital expenditure. A potential TikTok ban in 2025 presents both a risk and an opportunity.
Meta Stock Soars 70% in 2024 Despite Regulatory and Political Uncertainties
Meta Platforms' stock price increased 70% year-to-date in 2024 due to increased operating margin (156%) and AI investments, despite concerns about 2024 revenue guidance and capital expenditure. A potential TikTok ban in 2025 presents both a risk and an opportunity.
Progress
48% Bias Score
Dow Jones Stocks Poised for Growth in 2025: Merck and Nvidia Lead the Way
Wall Street analysts predict strong gains for select Dow Jones stocks in 2025, with Merck leading at 32% projected upside due to its Keytruda drug and pipeline, while Nvidia projects 28% growth despite recent market corrections; other pharma stocks show mixed outlooks.
Dow Jones Stocks Poised for Growth in 2025: Merck and Nvidia Lead the Way
Wall Street analysts predict strong gains for select Dow Jones stocks in 2025, with Merck leading at 32% projected upside due to its Keytruda drug and pipeline, while Nvidia projects 28% growth despite recent market corrections; other pharma stocks show mixed outlooks.
Progress
40% Bias Score
Dow Stocks Face Tepid Outlook Amidst Analyst Concerns
Wall Street analysts predict less than 5% growth for several major Dow Jones stocks in the next 12 months, including Apple (-3.3%), American Express, and Goldman Sachs, reflecting concerns that post-election gains are already priced in.
Dow Stocks Face Tepid Outlook Amidst Analyst Concerns
Wall Street analysts predict less than 5% growth for several major Dow Jones stocks in the next 12 months, including Apple (-3.3%), American Express, and Goldman Sachs, reflecting concerns that post-election gains are already priced in.
Progress
52% Bias Score
US Stocks Plunge on Profit-Taking, Highlighting Tech Sector Vulnerability
US stocks fell sharply on Friday, December 27, 2024, with the Dow Jones Industrial Average down approximately 350 points (0.7%), the S&P 500 down 1.2%, and the Nasdaq Composite down 1.6%, largely due to profit-taking in a thin trading market, particularly impacting tech giants; analysts cite the con...
US Stocks Plunge on Profit-Taking, Highlighting Tech Sector Vulnerability
US stocks fell sharply on Friday, December 27, 2024, with the Dow Jones Industrial Average down approximately 350 points (0.7%), the S&P 500 down 1.2%, and the Nasdaq Composite down 1.6%, largely due to profit-taking in a thin trading market, particularly impacting tech giants; analysts cite the con...
Progress
40% Bias Score
Contrasting Insider Trading Activity: Kelt Exploration's Buy vs. Sales at BCE, CIBC, and Loblaw
Recent insider trading activity shows Kelt Exploration Ltd.'s CEO, David Wilson, purchased 656,900 shares on December 17th, while BCE Inc., CIBC, and Loblaw Companies Ltd. experienced insider share sales between December 10th and 18th; these transactions totaled over \$9 million in proceeds.
Contrasting Insider Trading Activity: Kelt Exploration's Buy vs. Sales at BCE, CIBC, and Loblaw
Recent insider trading activity shows Kelt Exploration Ltd.'s CEO, David Wilson, purchased 656,900 shares on December 17th, while BCE Inc., CIBC, and Loblaw Companies Ltd. experienced insider share sales between December 10th and 18th; these transactions totaled over \$9 million in proceeds.
Progress
48% Bias Score
Apple Stock Soars: iPhone 17 Launch and AI to Fuel Growth
Apple's stock price has risen nearly 35% in 2024, exceeding the S&P 500's growth, driven by strong financials and the anticipated launch of the iPhone 17, which JPMorgan predicts will increase iPhone sales from 230 million units to 263 million units by 2027.
Apple Stock Soars: iPhone 17 Launch and AI to Fuel Growth
Apple's stock price has risen nearly 35% in 2024, exceeding the S&P 500's growth, driven by strong financials and the anticipated launch of the iPhone 17, which JPMorgan predicts will increase iPhone sales from 230 million units to 263 million units by 2027.
Progress
48% Bias Score
S&P 500 Soars 24.3% in 2024 Amidst Record High Office Vacancies
The S&P 500 index reached record highs in 2024, rising 24.3% due to Federal Reserve interest rate cuts and investor optimism following Donald Trump's election; however, high office vacancy rates signal potential economic shifts.
S&P 500 Soars 24.3% in 2024 Amidst Record High Office Vacancies
The S&P 500 index reached record highs in 2024, rising 24.3% due to Federal Reserve interest rate cuts and investor optimism following Donald Trump's election; however, high office vacancy rates signal potential economic shifts.
Progress
40% Bias Score
Bernstein Highlights Semiconductor Investment Opportunities Despite 2025 Slowdown
Bernstein analysts predict flat growth for wafer fab equipment in 2025 but see opportunities in semiconductor assembly (BE Semiconductor Industries) and AI-driven chipmaking (Infineon Technologies), with Infineon's AI revenue exceeding €500 million in FY2025 and €1 billion within two years.
Bernstein Highlights Semiconductor Investment Opportunities Despite 2025 Slowdown
Bernstein analysts predict flat growth for wafer fab equipment in 2025 but see opportunities in semiconductor assembly (BE Semiconductor Industries) and AI-driven chipmaking (Infineon Technologies), with Infineon's AI revenue exceeding €500 million in FY2025 and €1 billion within two years.
Progress
36% Bias Score
Biotech's Binary Week: Mesoblast Soars, Percheron Crashes
In the final week of 2023, contrasting fortunes played out in the Australian biotech sector as Mesoblast shares soared 50% following US FDA approval, while Percheron shares crashed over 90% after a failed drug trial, highlighting the high-risk, high-reward nature of the industry.
Biotech's Binary Week: Mesoblast Soars, Percheron Crashes
In the final week of 2023, contrasting fortunes played out in the Australian biotech sector as Mesoblast shares soared 50% following US FDA approval, while Percheron shares crashed over 90% after a failed drug trial, highlighting the high-risk, high-reward nature of the industry.
Progress
60% Bias Score